文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

贝达喹啉与氯法齐明单用及联用逐步诱导耐药过程中耐药性出现的体外监测:表型与基因型分析

In vitro monitoring of drug resistance emergence during stepwise induction of bedaquiline and clofazimine, alone and in combination: a phenotypic and genotypic analysis.
PubMed 文献 · J Antimicrob Chemother · 2025-01-01

本研究在含药固体培养基上以2倍递增浓度逐步体外诱导结核分枝杆菌耐药,比较贝达喹啉、氯法齐明单用及两药联用时的表型与耐药相关基因突变。结果显示氯法齐明单用所致耐药基因突变出现较晚(第四轮诱导,而贝达喹啉单用或联用为第二轮);联用与贝达喹啉单用均早期出现Rv0678突变,但联用以核苷酸缺失或插入为主,单用以单核苷酸多态性为主。

要点

  • 氯法齐明单用耐药基因突变出现较晚,为第四轮诱导,而贝达喹啉单用或两药联用为第二轮诱导。
  • 两药联用以Rv0678核苷酸缺失或插入为主要突变类型,单药诱导以Rv0678单核苷酸多态性为主。
  • 所有耐药菌株中贝达喹啉MIC与氯法齐明MIC均呈强相关。

核心结论

  • 贝达喹啉与氯法齐明联用出现Rv0678突变的时间与贝达喹啉单用一样早,但联用菌株以缺失和插入突变为主而非单核苷酸多态性。

研究设计与样本

  • 在含药固体培养基上以2倍递增浓度逐步体外诱导耐药结核分枝杆菌,药物为贝达喹啉、氯法齐明及两药联用,测定诱导耐药菌株的MIC并测序分析Rv0678、Rv1979c、atpE和pepQ等耐药相关基因。

主要发现

  • 氯法齐明单用所致耐药基因突变出现在第四轮诱导,而贝达喹啉单用或两药联用出现在第二轮诱导。
  • 两药联用诱导时Rv0678的核苷酸缺失或插入为主要突变类型,贝达喹啉或氯法齐明单用诱导时Rv0678的单核苷酸多态性为主要突变类型。
  • Rv0678突变发生于相对较低的贝达喹啉浓度暴露,atpE突变发生于较高的贝达喹啉浓度。
  • 无论何种药物暴露方式,所有耐药菌株中贝达喹啉MIC与氯法齐明MIC均呈强相关。

关键数值与推荐

  • 氯法齐明单用耐药基因突变出现在第四轮诱导,贝达喹啉单用或两药联用出现在第二轮诱导。
  • Rv0678突变发生于相对较低的贝达喹啉浓度暴露,atpE突变发生于较高的贝达喹啉浓度。
  • 所有耐药菌株中贝达喹啉MIC与氯法齐明MIC均呈强相关。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The co-resistance between bedaquiline and clofazimine raises significant concerns, as they are commonly co-administered as core drugs in drug-resistant TB regimens. The present study aimed to monitor drug resistance-associated gene mutations and the phenotypic change in Mycobacterium tuberculosis (Mtb) under a stepwise drug resistance induction in vitro using bedaquiline, clofazimine or combined drugs. METHODS: Drug-resistant Mtb strains were gradually induced in vitro on a drug-containing solid medium with a 2-fold increasing concentration of bedaquiline, clofazimine and their combination. The MIC of the induced drug-resistant Mtb strains was determined. The drug resistance-associated genes, including Rv0678, Rv1979c, atpE and pepQ, were sequenced and analysed. RESULTS: Unlike exposure to bedaquiline alone or the combination of these two drugs, clofazimine alone resulted in drug resistance gene mutations occurring later, specifically in the fourth round of induction as opposed to the second round of induction. Besides, nucleotide deletion or insertion in Rv0678 was the main mutation type for induction under the two-drug combination, while single-nucleotide polymorphisms (SNPs) in Rv0678 were the major mutation types when induced by bedaquiline or clofazimine alone. Rv0678 mutation happened at a relatively lower bedaquiline concentration exposure alone, while atpE mutation occurred at a higher bedaquiline concentration. Regardless of the drug exposure manner, a strong correlation between bedaquiline MICs and clofazimine MICs was observed in all drug resistance strains. CONCLUSIONS: Combined exposure to bedaquiline and clofazimine developed Rv0678 mutation as early as exposure to bedaquiline alone. However, rather than SNPs, deletion and insertion were the dominant mutation types in dual-drug exposure strain.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Chen S, Shang Y, Zheng J, et al. In vitro monitoring of drug resistance emergence during stepwise induction of bedaquiline and clofazimine, alone and in combination: a phenotypic and genotypic analysis. J Antimicrob Chemother. 2025. PMID: 39523472. doi:10.1093/jac/dkae405

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。